The Food and Drug Administration yesterday approved using Olumiant (baricitinib) to treat COVID-19 in hospitalized adults requiring supplemental oxygen, mechanical ventilation or extracorporeal membrane oxygenation (ECMO). The COVID-19 treatment was previously authorized for emergency use in hospitalized children and adults, and remains under EUA for hospitalized children.

In other news, FDA yesterday alerted health care providers and the public not to use the Skippack Medical Lab SARS-CoV-2 Antigen Rapid Test (Colloidal Gold) because the agency has not authorized or approved the test and it may produce false results. 

Related News Articles

Headline
Pfizer has submitted a request for the Food and Drug Administration to authorize a 10-microgram booster dose of its bivalent COVID-19 vaccine booster for…
Headline
Health care providers who treat uninsured or underinsured patients with commercially procured bebtelovimab, a COVID-19 monoclonal antibody therapy for…
Headline
Moderna Friday submitted its request that the Food and Drug Administration authorize for emergency use its bivalent COVID-19 vaccine for children and…
Headline
AHA will co-host a Sept. 27 Facebook Live event with AdventHealth on the importance of getting children vaccinated and boosted against COVID-19, which will…
Headline
Insured and uninsured Americans can receive the new bivalent Pfizer or Moderna COVID-19 booster and other COVID-19 vaccines at no cost as long as the federal…
Headline
The Biden Administration will make over 170 million doses of the bivalent COVID-19 vaccine booster available to Americans for free at pharmacies, doctor’s…